MMJ International

MMJ International Holdings is a clinical-stage pharmaceutical company specializing in the development of cannabis-derived prescription medicines for orphan diseases. The company focuses on conducting FDA-approved clinical trials to address unmet medical needs in neurology, specifically targeting Multiple Sclerosis and Huntington's Disease. MMJ utilizes proprietary extraction and purification processes to create pharmaceutical-grade cannabinoid formulations, such as MMJ-001 and MMJ-002. Operating under strict DEA and FDA regulatory frameworks, the company is one of the few entities authorized to import and research cannabis for botanical drug development in the United States. Their lead candidates are administered as oral capsules and aim to treat symptoms like spasticity and chorea.